Preclinical Safety: From In Vitro Assays to Human Dose Predictions (edX)

In this course about preclinical safety, students will learn methods for quantifying the safety of a potential drug. The three-week course starts with the origins of preclinical safety programs as well as preliminary safety testing for promising compounds in a drug program. The second week emphasizes in vivo safety studies in representative rodent and non-rodent preclinical animal species. In the final week, students will learn how the PK properties are used with efficacy data to predict the human efficacious dose and assist in drug formulation.

Students in the course should understand human anatomy. An understanding of both pharmacodynamics and pharmacokinetics will also be helpful. The course is designed in modules. Each module opens with a short video on a selected topic. The module continues with a short reading or exercise with an assessment activity. Each module will require approximately 1 hour to complete, and the course includes 15 modules. Two approaches to the course are recommended. One, a student might spend an hour per day on the course and complete all 15 modules in approximately three weeks. Two, a student with additional available time may be able to work through the entire course in just a single week or over an extended weekend.

Students signed up for the Audit Track have access to the instructional video materials. Students enrolled through the Verified Track have access to the instructional videos, the readings and activities, the assessments, as well as selected additional videos related to the primary instructional videos.

What you'll learn

- distinctions between pharmacology and toxicology

- origins of preclinical safety studies required by regulatory agencies

- common in vitro tests for safety risks

- the design of different in vivo preclinical safety studies

- the basis for calculating an investigational drug’s first-in-human dose

- processes for monitoring the safety of drugs that are already approved and in the hands of patients

Syllabus

week 1

pharmacology & toxicology

preclinical safety timeline

tragedies in drug safety

in vitro safety assays

risks from hERG channel inhibition

week 2

on-target toxicity

in vivo toxicology studies

drug-drug interactions

intra-family target selectivity

drug purity and safety

week 3

efficacy vs. safety risks

maximum recommended starting dose

safety in oncology drugs

preclinical safety concurrent with clinical trials

post-approval surveillance